The Race to Market: Building an Efficient Discovery Engine

Sep 28 2017


Are you confident in the integrity of your data? Every day, hundreds of scientists are forming the basis of drug discovery. Laboratory data forms the building blocks of the scientific work, and its quality is paramount to crucial business decisions and long term success. Take an in-depth look into potential quality risks and inefficiencies in research and explore measures to improve data quality in the drug discovery processes. Johnson & Johnson Innovation, JLABS (JLABS) and Janssen R&D invite you to an interactive workshop where attendees will work in groups to think about data handling dilemmas and their possible risks..

[This is an interactive workshop including small working groups during the day, therefore space is limited]

Presentations will cover the following topics:

  • A roadmap for bringing a drug to market
  • Dilemmas in discovery – a workshop
  • Reproducibility in research
  • A quality approach within Janssen R&D

8:30 AM | Registration and Networking Breakfast
9:00 AM | A roadmap for bringing a drug to market

  • Drug discovery process
  • Internal and external stakeholders
  • Opportunities and challenges

9:15 AM | Dilemmas in discovery - a workshop

  • An interactive session focusing on potential data handling dilemmas and their associated risks

10:00 AM | Discovery data integrity – a quality approach for Janssen R&D

  • Sponsorship and support
  • Training approach
  • Risk-based monitoring
  • Phase appropriate solutions

11:00 AM | Discussion and Q&A
11:15AM | Program Close

David Malwitz| Manager, Bioresearch Quality & Compliance, Janssen R&D read bio»
Lynn Young | Sr. Research Manager, Alliance Business & Portfolio Managements; Janssen R&D read bio»
Jackie Benson| VP Immunology SCI Innovation, Research Admin, Johnson & Johnson Innovation read bio»


$25 | General Public
$15 | Student/Academic 
$45 | At the door

329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It

Speaker Biographies:

David Malwitz | Manager, Bioresearch Quality & Compliance, Janssen R&D
David is responsible for the planning and execution of external strategy in the Non-regulated QA domain of Bioresearch Quality & Compliance. This includes implementing key systems and processes needed to establish a risk-based audit program, operationalizing strategic quality and compliance capabilities, and recruiting the right team and network across global R&D sites to enable a successful portfolio. In addition, David supports the internal quality maintenance program by leading internal and external assessments across multiple therapeutic areas and has led compliance integration efforts to ensure the successful alignment of acquired assets into the Janssen R&D organization. David began his career as a research scientist at Wyeth Research and Amgen. He has a M.S. in Organic Chemistry from Wright State University and B.S. in Chemistry from Cedarville University.

Lynn Young | Sr. Research Manager, Alliance Business & Portfolio Managements; Janssen R&D
Lynn enables the "business of science" for Discovery Immunology team at Janssen Research & Development. Her focus areas include driving the end-to-end contracts process, ensuring Healthcare Compliance for contracts, monitoring records management and promoting Discovery Data Integrity (DDI) practices. Lynn is a protein biochemist and began her career in the pharmaceutical industry at Tanabe Research Laboratories USA focusing on integrin targets. From there she moved to the RW Johnson Pharmaceutical Research Institute to support drug discovery in the Virology, Infectious Diseases and later the Immunology departments. In 2010, she transitioned to a strategy and operations team supporting the business needs within Research Immunology. Lynn has a M.S. in Biology from the University of California at Irvine and a B.A. in Biochemistry and Cell Biology from University of California at San Diego.

Jackie Benson | VP IMMUNOLOGY SCI INNOVATION, Research Admin Johnson & Johnson Innovation

Jackie is responsible for creating and implementing an external innovation plan focused on developing an industry-leading portfolio of Immunology Therapeutic Area investment opportunities on the West Coast. This work will help solidify Janssen as the partner of choice in a highly competitive landscape, and identify and deliver the best opportunities for value-generating collaborations supporting our Immunology scientific strategy.

In her previous role, Jackie launched and led the Estrela Venture within the Janssen Incubator, advancing innovative treatments for systemic lupus erythematosus (SLE). Jackie led the Estrela Venture to a number of key milestones, including the declaration of two new molecular entities, one of which recently achieved first patient dosed in SLE patients.

Jackie joined the Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Research Scientist in 2001, playing an instrumental role in the research and discovery of several flagship programs, including STELARA® (ustekinumab), for which she earned a Johnson Medal, and guselkumab. She received her B.S. in Biology from The Ohio State University, followed by her Ph.D. in Immunology from the College of Medicine at The Ohio State University, and was awarded a National Multiple Sclerosis Society postdoctoral fellowship at Stanford University School of Medicine.